On November 27, the 6th "ESG Leading Enterprise 2024" awards ceremony, co-hosted by Bloomberg Businessweek/Chinese Edition ("Bloomberg") and Deloitte, was held in Hong Kong. Sino Biopharm stood out from the participating companies for its outstanding performance in the ESG field, winning the "ESG Leading Enterprise" award. It also received the "Sustainable Supply Chain" award for its leading practices in building a sustainable supply chain. Jin Song, Vice President of Sino Biopharm and Head of the ESG Working and Management Committee, was invited to attend the ceremony to receive the awards and engaged in in-depth communication and exchanges with the organizers and experts from various fields.

The "Bloomberg Businessweek/Chinese Edition ESG Leading Enterprise 2024" selection event aims to recognize listed companies and asset management institutions with outstanding performance in the ESG field, and to encourage enterprises to continuously deepen their ESG strategies and enhance their ESG management levels in an environment of climate change and increasingly complex supply chains. This selection was assisted by the globally renowned accounting firm Deloitte in formulating the judging framework for Bloomberg. An independent judging panel conducted the review based on the performance of participating companies in categories such as ESG governance, targets, performance, environmental protection, and community projects, ensuring credibility and objectivity.

2024 marks the third year of Sino Biopharm's comprehensive promotion of its ESG CARE strategy. The various ESG governance enhancement projects advanced by the Group, combining its own development with social needs, have all made positive progress. As one of the Group's most representative ESG initiatives—the "Responsible Supply Chain Construction Project"—since 2022, it has achieved the improvement of the responsible supply chain system and management capabilities, the full coverage of the supplier ESG rules to core suppliers, and a deep influence on key secondary suppliers. The project organizes and encourages suppliers to conduct ESG management self-assessments, guiding them to deeply understand the ESG concept and comprehensively identify key areas for ESG improvement. At the meeting, Jin Song stated that the construction of a responsible supply chain represents the Group's determination to fulfill its industry and social mission as a leading Chinese pharmaceutical company. Sino Biopharm hopes to work with partners from all sectors to jointly lead the high-quality development of the industrial chain.

Winning these two major awards represents the full affirmation of Sino Biopharm's ESG management work and performance in recent years by professional ESG institutions, as well as full recognition of its level of sustainable supply chain construction. In the future, Sino Biopharm will continue to practice the ESG concept, enhance its ESG management level, and improve its sustainable supply chain construction. It will earnestly practice the Group's mission of "improving the quality and protecting the dignity of human life", seek health and well-being for more patients, and contribute to the sustainable development of the industry and even the world.